Thursday, March 19, 2015 8:07:47 AM
Revised 2/15/2015
Momenta's Corporate Development team is now turning its focus to building upon the company's existing pipeline of novel drugs, and leveraging the capabilities of its innovative technology through out-licensing and in-licensing opportunities.
If you are interested in pursuing a collaboration opportunity with Momenta Pharmaceuticals, or have a technology you wish to introduce to our team, we welcome you to contact us at businessdevelopment@momentapharma.com.
Out-licensing
We are interested in pursuing licensing opportunities with interested parties for pivotal development and commercialization of adomiparin (M118), a novel anticoagulant with the potential to be used in multiple settings including medical management of acute coronary syndromes (ACS), angioplasty, and coronary artery bypass graft surgery (CABG).
In-Licensing
We have an active internal development program; however, we are also interested in in-licensing opportunities that may broaden our analytical tool-set or complement our proprietary pipeline. We are seeking in-licensing opportunities in the disease areas of autoimmune, inflammation, and cancer. We also welcome ideas in other diseases where our analytical and characterization approach could aid in solving a research problem that could ultimately lead to novel drugs for patients in need.
http://www.momentapharma.com/about/business-development.php#
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM